Future Developments in Local Anesthetics

Future Developments in Local Anesthetics

Future Developments in Local Anesthetics

On this page

Extended-Release LAs - Long‑Lasting Blocks

  • Goal: Prolong analgesia (up to 72+ hours), ↓ opioid use, ↓ catheter need.
  • Mechanisms & Formulations:
    • Liposomal encapsulation (e.g., Exparel)
    • Polymer-based systems (microspheres, hydrogels)
    • Nanoparticles, prodrugs
  • Key Example: Exparel (Liposomal Bupivacaine)
    • Bupivacaine in DepoFoam (multivesicular liposomes).
    • Approved: Surgical site infiltration, interscalene block.
    • Duration: Up to 72 hours.
    • Caution: Avoid mixing with lidocaine/other LAs (disrupts liposomes); specific bupivacaine HCl ratios allowed.

    ⭐ Exparel (liposomal bupivacaine) offers analgesia for up to 72 hours via slow release from DepoFoam technology.

  • Advantages:
    • Sustained pain relief, ↓ opioid needs.
    • ↓ systemic toxicity risk (lower $C_{max}$).
    • Improved patient satisfaction.
  • Challenges:
    • Higher cost.
    • Fixed dose (no easy titration).
    • Risk of prolonged motor block if not precisely placed. Exparel DepoFoam particle characterization and release

Novel LA Agents - Safer & Targeted

  • Primary Goals:
    • Enhanced safety: ↓Systemic toxicity (cardiac, CNS), ↓Neurotoxicity.
    • Improved efficacy: Prolonged duration, site-specificity.
  • Key Approaches & Examples:
    • Liposomal Formulations (e.g., Exparel - Liposomal Bupivacaine):
      • Mechanism: Slow drug release from lipid vesicles.
      • Benefits: Extended analgesia (up to 72 hrs), ↓peak plasma levels, ↓systemic toxicity.
      • Use: Post-op pain, nerve blocks.
    • Site-Specific/Activated Agents:
      • Prodrugs: Activated by local conditions (inflammation, enzymes).
      • Targeted delivery: Nanoparticles, microspheres.
    • $Na_v$ Subtype-Specific Blockers:
      • Target pain-transmitting $Na_v$ channels (e.g., $Na_v$1.7, $Na_v$1.8).
      • Potential: Analgesia without motor block or cardiotoxicity; largely investigational.
    • Long-Acting Toxins (e.g., Neosaxitoxin):
      • Potent, ultra-long duration. Research ongoing for safety.

⭐ Exparel (liposomal bupivacaine) can provide analgesia for up to 72 hours, significantly reducing post-operative opioid requirements. oka

Emerging Technologies - Anesthesia's New Wave

  • Liposomal Formulations (e.g., Exparel):
    • Prolonged action (up to 72 hrs).
    • ↓ Systemic toxicity.
    • Site-specific delivery.

    ⭐ Liposomal bupivacaine (Exparel) offers extended analgesia up to 72 hours, reducing opioid needs.

  • Stimulus-Responsive Systems:
    • LA release by pH, temp, ultrasound, light.
    • On-demand pain relief.
    • E.g., Ultrasound-triggered release.
  • Nanotechnology Delivery:
    • Nanoparticles, nanoemulsions.
    • ↑ Solubility, stability, penetration.
    • Targeted delivery, ↓ side effects. Nanoparticle delivery of local anesthetics
  • Site-Specific LA Analogs:
    • Target specific Na+ channels (e.g., Nav1.7).
    • Aim: Analgesia without motor block.
  • Needle-Free Delivery:
    • Jet injectors, advanced topical patches.
    • ↑ Patient comfort_._

High‑Yield Points - ⚡ Biggest Takeaways

  • Liposomal LAs (e.g., Exparel) for prolonged analgesia.
  • Nanocarriers (e.g., microspheres) for site-specific delivery, ↑efficacy, ↓toxicity.
  • Development of safer LAs with less cardiotoxicity & neurotoxicity.
  • Novel adjuvants (e.g., capsaicin analogs) to prolong action, reduce LA dose.
  • Nav1.7 inhibitors as subtype-specific blockers for selective analgesia (no motor block).
  • Reversible LAs for better control and rapid recovery.
  • Needle-free delivery (e.g., jet injectors, patches) for painless application.

Practice Questions: Future Developments in Local Anesthetics

Test your understanding with these related questions

Anaesthetic agent causing analgesia?

1 of 5

Flashcards: Future Developments in Local Anesthetics

1/8

Symptoms such as metallic taste, perioral numbness, visual changes, twitching, and seizures in a patient on local anesthesia point towards _____

TAP TO REVEAL ANSWER

Symptoms such as metallic taste, perioral numbness, visual changes, twitching, and seizures in a patient on local anesthesia point towards _____

local anesthetic systemic toxicity (LAST)

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial